Tabula Rasa HealthCare, Inc. to Post FY2023 Earnings of ($0.18) Per Share, SVB Leerink Forecasts (NASDAQ:TRHC)

Tabula Rasa HealthCare, Inc. (NASDAQ:TRHCGet Rating) – SVB Leerink upped their FY2023 earnings per share (EPS) estimates for shares of Tabula Rasa HealthCare in a research note issued on Wednesday, January 18th. SVB Leerink analyst S. Davis now anticipates that the company will earn ($0.18) per share for the year, up from their prior estimate of ($0.19). The consensus estimate for Tabula Rasa HealthCare’s current full-year earnings is ($2.12) per share.

A number of other equities research analysts have also commented on the company. Piper Sandler lowered their price target on Tabula Rasa HealthCare from $6.00 to $4.00 and set a “neutral” rating for the company in a research report on Monday, November 7th. StockNews.com upgraded Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a research note on Thursday, October 20th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $8.10.

Tabula Rasa HealthCare Trading Down 0.7 %

NASDAQ TRHC opened at $5.97 on Friday. The firm has a market capitalization of $161.93 million, a P/E ratio of -1.03 and a beta of 1.58. The business has a fifty day simple moving average of $4.50 and a 200 day simple moving average of $4.31. Tabula Rasa HealthCare has a 12 month low of $2.09 and a 12 month high of $14.42.

Tabula Rasa HealthCare (NASDAQ:TRHCGet Rating) last released its quarterly earnings results on Thursday, November 3rd. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.78). The company had revenue of $77.10 million during the quarter, compared to analysts’ expectations of $73.68 million. Tabula Rasa HealthCare had a negative net margin of 46.03% and a negative return on equity of 472.90%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Teachers Retirement System of The State of Kentucky bought a new position in Tabula Rasa HealthCare in the 3rd quarter worth about $25,000. Jacobs Levy Equity Management Inc. boosted its stake in Tabula Rasa HealthCare by 258.9% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 626,810 shares of the company’s stock worth $3,009,000 after purchasing an additional 452,154 shares during the period. Two Sigma Advisers LP boosted its stake in Tabula Rasa HealthCare by 30.9% in the 3rd quarter. Two Sigma Advisers LP now owns 330,014 shares of the company’s stock worth $1,584,000 after purchasing an additional 77,814 shares during the period. Two Sigma Investments LP boosted its stake in Tabula Rasa HealthCare by 180.9% in the 3rd quarter. Two Sigma Investments LP now owns 314,226 shares of the company’s stock worth $1,508,000 after purchasing an additional 202,352 shares during the period. Finally, Engineers Gate Manager LP bought a new position in Tabula Rasa HealthCare in the 3rd quarter worth about $54,000. Institutional investors own 60.90% of the company’s stock.

Insider Buying and Selling at Tabula Rasa HealthCare

In other news, CFO Thomas Cancro purchased 11,500 shares of the business’s stock in a transaction dated Monday, December 12th. The stock was bought at an average price of $4.34 per share, for a total transaction of $49,910.00. Following the purchase, the chief financial officer now owns 211,500 shares of the company’s stock, valued at $917,910. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Thomas Cancro purchased 11,500 shares of the business’s stock in a transaction dated Monday, December 12th. The stock was bought at an average price of $4.34 per share, for a total transaction of $49,910.00. Following the purchase, the chief financial officer now owns 211,500 shares of the company’s stock, valued at $917,910. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael J. Purcell sold 10,000 shares of the stock in a transaction on Friday, December 9th. The stock was sold at an average price of $4.26, for a total value of $42,600.00. Following the transaction, the director now owns 88,514 shares of the company’s stock, valued at approximately $377,069.64. The disclosure for this sale can be found here. Corporate insiders own 7.25% of the company’s stock.

About Tabula Rasa HealthCare

(Get Rating)

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. The company operates in two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise medication therapy management software, a cloud-based platform designed to aid in the identification and resolution of medication and health-related problems.

Further Reading

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.